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Background: Transarterial chemoembolization (TACE) with drug-eluting beads (DEB) is a new treatment
modality. Little is known about prognostic factors affecting survival after DEB TACE for patients with
hepatocellular carcinoma (HCC).
Methods: Patients who underwent TACE with doxorubicin DEB for unresectable HCC during 2006–2008
were studied. Survival was calculated from the day of first transcatheter therapy. Survival analysis was
performed using Kaplan–Meier estimations. Survival curves were compared using the log-rank test.
Results: Fifty patients underwent chemoembolization with doxorubicin DEB. They included 39 women
and 11 men, with a median age of 57.5 years (range 28–91 years). Eighteen patients died during the study
period and 32 remained alive. Overall survival rates at 6 months, 1 year and 2 years from the first
administration of doxorubicin DEB TACE were 71%, 65% and 51%, respectively. Prognostic factors
found to be significant on univariate analysis were Child–Pugh class, Okuda staging, bilirubin > 2 mg/dl,
albumin < 3.0 g/dl, Model for End-stage Liver Disease (MELD) score, serum alphafetoprotein (AFP),
Cancer of the Liver Italian Programme (CLIP) score, tumour satisfying Milan criteria, Eastern Cooperative
Oncology Group (ECOG) performance status (PS) and Barcelona Clinic Liver Cancer (BCLC) staging.
Conclusions: Child–Pugh class, Okuda staging, bilirubin > 2 mg/dl, albumin < 3 g/dl, MELD score,
serum AFP, CLIP score, Milan criteria, ECOG PS and BCLC staging were found to be prognostic markers
of survival after treatment with doxorubicin DEB TACE in patients with unresectable HCC.
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Introduction
Hepatocellular carcinoma (HCC) is a lethal malignancy, the inci-
dence of which has continually increased in the USA over the past
two decades.1 Transplantation and resection are curative therapies
for HCC. The majority of patients, however, are not eligible for
surgery because of advanced tumour, multifocal disease or poor
liver reserve.2 Conventional transarterial chemoembolization
(TACE) has been used as palliative treatment for patients with
HCC who are ineligible for resection or transplantation. The sur-
vival benefit of this treatment over supportive care has been
shown by two prospective randomized controlled trials carried
out in 2002 in patients with unresectable HCC.3,4
Drug-eluting beads (DEB), which can be loaded with doxoru-
bicin, represent a novel drug delivery system for chemoem-
bolization. A slow and sustained release of drug is expected after
intra-arterial delivery of DEB. Clinical studies by Varela et al.5
and Malagari et al.6 have reported this new drug delivery method
to be safe and efficacious in the treatment of HCC. DEB TACE
has been proposed to have a better pharmacokinetic profile than
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conventional TACE and to result in decreased systemic adverse
effects.7
Factors which predispose patients to develop hepatic failure
and related complications after transarterial treatment are gener-
ally identified as exclusion criteria during patient selection. Large
tumours, poor liver reserve and portal vein thrombosis (PVT)
have been associated with poorer outcomes in patients treated
with conventional chemoembolization.8–10 Because DEB TACE
is a new treatment modality, little is known about prognostic
factors affecting survival after DEB TACE in patients with HCC.
The aim of this study was to identify prognostic factors which
influence survival from the time of transcatheter therapy in
patients with unresectable HCC treated with doxorubicin DEB
chemoembolization.
Materials and methods
Patient selection
The study was approved by the local institutional review board.
Consecutive patients with HCC who underwent chemoembo-
lization with doxorubicin DEB at a single institution during a
period of 3 years (January 2006 to December 2008) were
reviewed. A prospective database for patients treated after July
2008 was used, and data were collected retrospectively from case
records for patients treated between January 2006 and June
2008. Patients were excluded if they had: (i) undergone
resection; (ii) undergone radiofrequency ablation; (iii) received
conventional chemoembolization, bland embolization or radi-
oembolization with yttrium 90 (Y-90); (iv) received therapy with
more than one type of embolic agent, or (v) received systemic
chemotherapy such as sorafenib (Nexavar; Bayer Corp., Pitts-
burgh, PA, USA).
The American Association for the Study of Liver Diseases
(AASLD) guidelines11 were used to diagnose HCC. This diagnosis
was made if dynamic computed tomography (CT) or magnetic
resonance imaging (MRI) showed a mass with typical vascular
pattern, arterial enhancement and portal venous ‘washout’. For
lesions sized 1–2 cm, two different studies were used to detect a
typical pattern; for nodules >2 cm in diameter, only one typical
study was used. Lesions with doubtful or inconclusive features on
imaging were biopsied.
Okuda staging, Cancer of the Liver Italian Programme (CLIP)
score and the Barcelona Clinic Liver Cancer (BCLC) staging
system (Tables 1–3) have been used to stage HCC.12–14 The Eastern
Cooperative Oncology Group (ECOG) system has been used to
grade performance status (PS).15
Data collection
Demographic (age, gender, ethnicity), clinical (aetiology, compli-
cations), laboratory parameters (bilirubin, albumin, creatinine,
international normalized ratio [INR], alphafetoprotein [AFP])
and imaging (number of lesions, distribution, size, PVT) data
were collected from patient case records. All patients underwent
CT or MRI within 1 month before the procedure to assess tumour
Table 1 Okuda staging
0 points 1 point
Tumour size <50% of liver >50% of liver
Ascites No Yes
Albumin >3.0 g/dl <3.0 g/dl
Bilirubin <3.0 mg/dl >3.0 mg/dl
Stage I = 0 points; Stage II = 1,2 points; Stage III = 3,4 points
Table 2 Cancer of the Italian Liver Programme (CLIP) staging
0 points 1 point 2 points
Child–Pugh class A B C
Alphafetoprotein <400 400
Portal vein thrombosis Absent Present
Tumour Single, <50% Multiple, <50% Multiple, >50%
Early stage = 0 points; intermediate stage = 1–3 points; advanced stage = 4–6 points
Table 3 Barcelona Clinic Liver Cancer (BCLC) staging
Performance status Tumour stage Okuda stage Liver function
Stage A
A1 0 Single < 5 cm I No portal hypertension
A2 0 Single < 5 cm I Portal hypertension, normal bilirubin
A3 0 Single < 5 cm I Portal hypertension, elevated bilirubin
A4 0 Up to 3, <3 cm I–II Child–Pugh class A–B
Stage B 0 Large multi-nodular I–II A–B
Stage C 1–2 Vascular invasion or extrahepatic disease I–II A–B
Stage D 3–4 Any III C
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burden and presence of PVT.Hepatocellular carcinoma withmore
than five discrete nodules was referred to as diffuse tumour. Mean
tumour size was calculated by the sum of the longest diameter of
all measurable tumours.
Procedure
The type of therapy patients received was determined in a multi-
disciplinary liver tumour conference. Transcatheter therapy was
performed via femoral artery approach under moderate sedation.
Coeliac and superior mesenteric arteriograms were obtained to
assess the arterial anatomy of the liver, tumour vasculature and
portal vein patency. The chemotherapeutic agents were infused
into the hepatic artery supplying the tumour(s). Patients who
underwent chemoembolization with doxorubicin DEB received
300–500 mm and 500–700 mm LC beads (Biocompatibles PLC,
Farnham, UK) impregnated with 75 mg of doxorubicin in each
vial, or 100–300 mm LC beads impregnated with 50 mg of doxo-
rubicin in each vial. Subsegmental or segmental chemoemboliza-
tion were performed whenever possible. Flow in main and branch
arteries supplying tumours were kept patent tomaintain access for
potential subsequent interventions. All patients were kept under
observation for a period of 24 h and analgesia was administered as
necessary.
Follow-up
Follow-up cross-sectional imaging (contrast-enhanced CT or
MRI) was performed 3–4 weeks after treatment. Further treat-
ments were based on clinical evaluation, laboratory values and
imaging response. Patients with progressive disease underwent
repeat treatments with the same modality. Patients with stable
disease were followed with cross-sectional imaging every 3
months.
Statistics
Survival time is defined as the time from the first doxorubicin
DEB chemoembolization to the date of death. Survival analysis
was performed using Kaplan–Meier estimation. In univariate
analysis, survival estimates were compared with log-rank test in
the Kaplan–Meier method. Multivariate analysis was not carried
out as the small sample size and low number of events per variable
in the study could potentially lead to inconclusive results. spss
Graduate Version 16.0 (SPSS, Inc., Chicago, IL, USA) was used for
all statistical computations.
Results
A total of 50 patients with HCC who underwent chemoemboliza-
tion with doxorubicin DEB and satisfied the inclusion criteria
were included in the study. They included 39 women and 11 men,
with a median age of 57.5 years (range 28–91 years). Eighteen
patients (36%) died during the study period. Demographic, clini-
cal, laboratory, tumour staging and imaging characteristics are
summarized in Table 4.
The median duration of follow-up was 359 days (range 33–984
days). Median survival could not be calculated because more than
50% of the patients were alive at the end of the study period.
Overall survival rates at 6 months, 1 year and 2 years from the first
administration of doxorubicin DEB were 71%, 65% and 51%,
respectively.
Univariate analysis
Univariate analyses of patient- and tumour-related variables along
with various prognostic scoring systems are given in Table 5. Prog-
nostic factors found to be associated with survival on univariate
analysis were Child–Pugh classes A and B, early Okuda stage,
bilirubin < 2.0 mg/dl, albumin > 3.0 g/dl, lowModel for End-stage
Liver Disease (MELD) score, AFP < 400 ng/ml, CLIP score < 3,
tumour within the Milan criteria, ECOG PS of 0 and early-
intermediate BCLC stages. Age, gender, ethnicity, PVT, creatinine,
INR and tumour size were not found to be significant prognostic
factors.
Discussion
Chemoembolization with doxorubicin DEB is a novel drug deliv-
ery system which performs the dual function of vascular embo-
lization and intra-tumour drug delivery. Studies by Varela et al.
and Malagari et al. demonstrate that chemoembolization is an
effective procedure with a favourable pharmacokinetic profile.5,6
Identifying the subset of patients with unresectable HCC, in
whom doxorubicin DEB TACE can prolong survival, is critical to
improving clinical outcome.
Univariate analysis in this study showed Child–Pugh class,
Okuda staging, bilirubin > 2 mg/dl, albumin < 3.0 g/dl, MELD
score, serum AFP, CLIP score, Milan criteria, ECOG PS and BCLC
staging to be significant prognostic factors for survival. Most of
the earlier studies investigating prognostic factors for transcath-
eter therapies have focused on conventional chemoembolization.
Table 6 summarizes the various prognostic factors for survival in
patients with unresectable HCC in some of the published
studies.8,9,16–21 Child–Pugh score and tumour size and stage have
been found to be significant predictors of survival after con-
ventional chemoembolization in most studies.8,9,17 The results of
the current study are comparable with those of conventional
chemoembolization as both Child–Pugh score and tumour stage
(as assessed by Okuda and BCLC staging) were found to be prog-
nostic factors in this study. However, tumour size and PVT, which
were among the prognostic factors for conventional chemoembo-
lization, were not found to influence survival after treatment with
DEB in the present study.
Advanced tumour stage (tumour burden > 50% of liver), infil-
trative type of tumour, poor liver function (bilirubin > 2.0 mg/dl;
albumin < 3.0 g/dl; elevated AST/ALT), and presence of PVT were
found to be prognostic factors for survival after treatment with
Y-90 radioembolization.20,21 In the current study, elevated biliru-
bin and elevated AFP were found to be prognostic factors on
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Table 4 Demographic and clinical characteristics
Patient characteristics Category n (%)
Age at diagnosis, years Median (range) 57.50 (28–91)
Gender Male 39 (78.0%)
Female 11 (22.0%)
Ethnicity White 37 (74.0%)
African-American 6 (12.0%)
Other 7 (14.0%)
Aetiology HCV 24 (48.0%)
HBV 6 (12.0%)
ALD 7 (14.0%)
Cryptogenic 7 (14.0%)
Others 6 (12.0%)
Child–Pugh class A 24 (48.0%)
B 14 (28.0%)
C 12 (24.0%)
MELD score Median (range) 11.0 (7–28)
Tumour characteristics Uni-nodular 26 (52.0%)
Multi-nodular (2–5 nodules) 15 (30.0%)
Diffuse (>5 nodules) 9 (18.0%)
Mean tumour size 5.49 cm (1.0–20.7 cm)
Portal vein thrombosis 12 (24.0%)
Satisfying Milan criteria 31 (62.0%)
Bilirubin, mg/dl Median (range) 1.6 (0.4–10.7)
Albumin, g/dl Median (range) 2.8 (1.8–5.0)
INR Median (range) 1.2 (0.9–1.9)
Creatinine, mg/dl Median (range) 1.0 (0.2–9.8)
AFP, ng/l Median (range) 43.7 (5–2400)
AFP <400 ng/l 43 (86.0%)
>400 ng/l 7 (14.0%)
ECOG PS 0 33 (66.0%)
1 15 (30.0%)
2 2 (4.0%)
BCLC staging Stage A
A1 0 (0.0%)
A2 7 (14.0%)
A3 6 (12.0%)
A4 2 (4.0%)
Stage B 9 (18.0%)
Stage C 8 (16.0%)
Stage D 18 (36.0%)
CLIP staging
0 7 (14.0%)
1 12 (24.0%)
2 10 (20.0%)
3 10 (20.0%)
4–6 11 (22.0%)
Okuda staging
I 24 (48.0%)
II 14 (28.0%)
III 12 (24.0%)
HCV, hepatitis C virus; HBV, hepatitis B virus; ALD, alcoholic liver disease; MELD, Model of End-stage Liver Disease; INR, international normalized
ratio; AFP, alphafetoprotein; ECOG, Eastern Cooperative Oncology Group; PS, performance status; BCLC, Barcelona Clinic Liver Cancer; CLIP,
Cancer of the Liver Italian Programme
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univariate analysis. The BCLC staging takes serum AFP, bilirubin
levels and PS into consideration, and BCLC stage was found to be
a prognostic factor in this study. Several studies have shown that
Child–Pugh classification is one of the most powerful predictors
of survival after transarterial chemoembolization.9,17,18,22 Georgia-
des et al. compared the prognostic accuracy of 12 HCC tumour
staging systems and found the Child–Pugh scoring system to be
the most accurate for predicting survival after conventional
chemoembolization.23 In the current study Child–Pugh class and
MELD score were both found to be predictors of survival, with
1-year survival rates in Child–Pugh classes A, B and C of 82%,
75% and 50%, respectively. Unlike this study, most of the existing
clinical studies on treatment with doxorubicin DEB TACE have
excluded patients in advanced stages, such as those with PVT and
those in Child–Pugh class C.5,24
The presence of PVT has traditionally been considered as a
contraindication for transarterial therapy.9,10 However, it was not
found to influence overall survival in the current study. Chung
et al. and Lee et al. also demonstrated that PVT did not adversely
affect survival after conventional chemoembolization if a proper
technique was employed.25,26 During transcatheter therapy for
patients with PVT, super-selective embolization techniques were
Table 5 Univariate analysis of prognostic factors
Variable Category n (events) 1 year 2 years HR (95% CI) P-value
Age at diagnosis <60 years 27 (10) 77% 61% 1.1 (0.4–3.6) 0.819
>60 years 23 (8) 74% 55%
Gender Male 39 (12) 64% 52% 1.3 (0.7–2.3) 0.291
Female 11 (6) 72% 64%
Ethnicity White 37 (13) 71% 62% 0.6 (0.2–2.1) 0.372
Non-White 13 (5) 83% 63%
Child–Pugh class A 24 (6) 82% 73% 6.1 (1.7–22.3) 0.002
B 14 (4) 75% 58% 1.3 (0.3–5.5)
C 12 (8) 50% 0%
MELD score <15 36 (10) 75% 67% 1.1 (0.9–1.2) 0.01
>16 14 (8) 57% 29%
Okuda stage I 24 (3) 90% 67% 6.6 (1.4–30.6) 0.005
II 14 (9) 67% 24% 5.2 (0.9–29.2)
III 12 (6) 48% 0%
AFP <400 ng/l 43 (8) 81% 74% 3.9 (1.4–11.2) 0.005
>400 ng/l 7 (10) 29% 14%
Portal vein Thrombosed 12 (5) 58% 40% 0.4 (0.1–1.1) 0.128
Patent 38 (13) 73% 64%
Bilirubin <2 mg/dl 32 (9) 81% 73% 2.8 (1.0–7.8) 0.038
>2 mg/dl 18 (9) 50% 25%
Albumin >3.0 g/dl 19 (4) 88% 67% 5.3 (1.1–23.6) 0.015
<3.0 g/dl 31 (14) 46% 35%
Tumour burden Uni-nodular 26 (8) 70% 62% 1.3 (0.7–2.6) 0.100
Multi-nodular 15 (4) 73% 48% 1.1 (0.6–2.1)
Diffuse 9 (6) 44% 0%
Milan criteria Within 31 (10) 76% 58% 0.35 (0.1–0.9) 0.038
Beyond 19 (8) 47% 31%
CLIP score <3 29 (5) 89% 70% 7.3 (2.0–25.0) <0.001
3 21 (13) 35% 23%
BCLC stage Early-intermediate 32 (8) 73% 62% 3.9 (1.3–11.6) 0.009
Advanced 18 (10) 28% 0%
ECOG PS 0 33 (5) 82% 82% 4.1 (2.0–8.3) <0.001
1–2 17 (13) 35% 12%
HR, hazard ratio; 95% CI, 95% confidence interval; MELD, Model of End-stage Liver Disease; AFP, alphafetoprotein; CLIP, Cancer of the Liver Italian
Programme; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status
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used during this study, when feasible, which may partially explain
the result.
The limitations of this study include its small number of
patients and relatively short-term follow-up; thus the results must
be taken as preliminary. Despite its limitations, the variables iden-
tified as prognostic factors are in concurrence with the risk factors
for conventional chemoembolization. The results obtained in the
study can be used as a guide to design further prospective studies.
Conclusions
Chemoembolization with doxorubicin DEB is a novel drug deliv-
ery system used as palliative treatment in patients with unresect-
able HCC. Appropriate patient selection remains the most
important factor able to influence clinical outcome. Serum
albumin level, bilirubin level, serum AFP, liver reserve (Child–
Pugh class and MELD score), HCC staging (by Okuda staging,
Milan criteria, CLIP score and BCLC staging) and PS as assessed
by ECOG classification were found to be predictors of survival.
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